2020
DOI: 10.1093/bioinformatics/btaa016
|View full text |Cite
|
Sign up to set email alerts
|

ABEMUS: platform-specific and data-informed detection of somatic SNVs in cfDNA

Abstract: Motivation The use of liquid biopsies for cancer patients enables the non-invasive tracking of treatment response and tumor dynamics through single or serial blood drawn tests. Next-generation sequencing assays allow for the simultaneous interrogation of extended sets of somatic single-nucleotide variants (SNVs) in circulating cell-free DNA (cfDNA), a mixture of DNA molecules originating both from normal and tumor tissue cells. However, low circulating tumor DNA (ctDNA) fractions together wit… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 8 publications
(3 citation statements)
references
References 41 publications
0
3
0
Order By: Relevance
“…Researchers are actively exploring somatic variations in circulating cfDNA as a means of early cancer detection across a range of cancer types 13 , 15 , 16 , including gastric 17 , colorectal 18 , lung 19 , breast 20 , early-stage lung 21 , and late-stage human malignancies 22 . The ABEMUS 23 is geared towards identifying somatic single-nucleotide variants in cfDNA for both cancer detection and monitoring recurrent cancer growth using sequencing data from cancer patients 24 .…”
Section: Related Workmentioning
confidence: 99%
“…Researchers are actively exploring somatic variations in circulating cfDNA as a means of early cancer detection across a range of cancer types 13 , 15 , 16 , including gastric 17 , colorectal 18 , lung 19 , breast 20 , early-stage lung 21 , and late-stage human malignancies 22 . The ABEMUS 23 is geared towards identifying somatic single-nucleotide variants in cfDNA for both cancer detection and monitoring recurrent cancer growth using sequencing data from cancer patients 24 .…”
Section: Related Workmentioning
confidence: 99%
“…With the addition of unique molecular identifiers (UMI) cfDNA fragments can be tagged before amplification steps which enable in silico correction of these biases downstream. Computational algorithms such as iDES [ 123 ], PEC [ 125 ], TNER [ 126 ], ABEMUS [ 127 ] and SiNVICT [ 128 ] can correct for stereotypical PCR errors which become especially relevant at lower VAFs detection limits [ 123 ]. Although using different estimation models, most of these algorithms calculate and remove background mutation error counts based on healthy references.…”
Section: Genetic Analysis Of Circulating Cfdna In Patients With Hnsccmentioning
confidence: 99%
“…Reference models are built across a single or a collection of WES or TS sequencing control samples, profiled with the same platform, using a fast and efficient multi-threaded cumulative pileup strategy based on ( Valentini et al , 2019 ). Specifically, synggen generates: (i) a Read Depth Model ( RDM ), which measures the average intra-sample depth of coverage variability by calculating the probability, across all input files, of observing sequencing reads at any captured genomic region and position; only reads aligning at the lowest genomic coordinate are considered when paired-end data is used; (ii) a Quality Model ( QM ), which measures the distribution of base qualities across sequencing read positions; (iii) Position-Based Error ( PBE ), which measures for each captured genomic position [not representing a common single nucleotide polymorphism (SNP)] the probability of observing platform-specific systematic errors supported by high quality reads and bases ( Casiraghi et al , 2020 ). When paired-end data are used to generate the reference models, insert size statistics are also computed and embedded in the RDM model.…”
Section: Approachmentioning
confidence: 99%